Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for the AKT Inhibitor, Capivasertib for Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA, AKT1 or PTEN Alterations.
In: Contify Life Science News, 2024-03-27
Zeitungsartikel
Zugriff:
Titel: |
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for the AKT Inhibitor, Capivasertib for Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA, AKT1 or PTEN Alterations.
|
---|---|
Zeitschrift: | Contify Life Science News, 2024-03-27 |
Veröffentlichung: | 2024 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|